ShockWave Medical, Inc. (SWAV)
May 31, 2024 - SWAV was delisted (reason: acquired by JNJ)
334.75
0.00 (0.00%)
Inactive · Last trade price
on May 30, 2024
ShockWave Medical Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for ShockWave Medical stock had an average target of 304, with a low estimate of 210 and a high estimate of 360.
Analyst Consensus: Hold
* Price targets were last updated on Apr 8, 2024.
Analyst Ratings
The average analyst rating for SWAV stock from 10 stock analysts was "Hold". This means that analysts believed this stock was likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 2 | 2 | 0 |
| Buy | 3 | 3 | 3 | 1 | 1 | 1 |
| Hold | 3 | 3 | 3 | 10 | 10 | 9 |
| Sell | 1 | 1 | 1 | 1 | 1 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 12 | 14 | 14 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| CL King | CL King | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Apr 8, 2024 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $361 → $335 | Buy → Hold | Downgrades | $361 → $335 | +0.07% | Apr 8, 2024 |
| Deutsche Bank | Deutsche Bank | Strong Buy → Hold Downgrades $270 → $335 | Strong Buy → Hold | Downgrades | $270 → $335 | +0.07% | Apr 8, 2024 |
| Morgan Stanley | Morgan Stanley | Buy → Hold Downgrades $285 → $335 | Buy → Hold | Downgrades | $285 → $335 | +0.07% | Apr 8, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy → Hold Downgrades $263 → $335 | Strong Buy → Hold | Downgrades | $263 → $335 | +0.07% | Apr 5, 2024 |
Financial Forecast
Revenue This Year
946.59M
from 730.23M
Increased by 29.63%
Revenue Next Year
1.16B
from 946.59M
Increased by 22.02%
EPS This Year
5.27
from 3.85
Increased by 36.81%
EPS Next Year
6.31
from 5.27
Increased by 19.71%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 986.0M | 1.2B | 1.5B | ||
| Avg | 946.6M | 1.2B | 1.4B | ||
| Low | 899.1M | 1.1B | 1.2B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 35.0% | 30.0% | 30.8% | ||
| Avg | 29.6% | 22.0% | 21.2% | ||
| Low | 23.1% | 12.7% | 5.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 5.57 | 7.14 | 8.95 | ||
| Avg | 5.27 | 6.31 | 7.41 | ||
| Low | 4.83 | 5.46 | 6.49 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 44.5% | 35.6% | 41.9% | ||
| Avg | 36.8% | 19.7% | 17.4% | ||
| Low | 25.5% | 3.6% | 2.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.